27 results
424B5
BHVN
Biohaven Ltd.
19 Apr 24
Prospectus supplement for primary offering
6:02am
assessment. All cohorts have proceeded as initially planned without any cohort expansion or interruption.
To date, BHV-1300 has been safe and well
424B5
BHVN
Biohaven Ltd.
17 Apr 24
Prospectus supplement for primary offering
4:01pm
for each cohort before next dose group; review includes cumulative safety, pharmacokinetics and pharmacodynamic assessment. All cohorts have proceeded
8-K
EX-99.1
BHVN
Biohaven Ltd.
29 Feb 24
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
4:16pm
for assessment of distinct target concentrations over a wide range, above and below projected efficacious EC50 drug concentrations, not previously feasible … in 1Q 2024 and the Company expects preliminary results in late 1Q 2024/early 2Q 2024. The FDA indicated that the MAD assessment of BHV-1300 should
8-K
EX-99.1
d2cr me9bkaqrkg
8 Jan 24
Regulation FD Disclosure
7:30am
10-Q
46ill3 46di
9 Nov 22
Quarterly report
4:19pm
8-K
EX-99.1
ghdb5kgj
9 Nov 22
Biohaven LTD. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
4:05pm
424B4
53b5lby
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
v5yb4r27z09ksxwblf
20 Oct 22
IPO registration (amended)
10:00am
S-1
izv6w bitui5p6c7w7
18 Oct 22
IPO registration
4:03pm
DRS
ks14w
11 Oct 22
Draft registration statement
12:00am
10-12B/A
EX-99.1
b17tct5k dr
20 Sep 22
Registration of securities (amended)
6:30am
10-12B/A
EX-99.1
21igv8h0r8mfzgsedp
14 Sep 22
Registration of securities (amended)
5:25pm
10-12B/A
EX-99.1
r6vs nm2n
7 Sep 22
Registration of securities (amended)
7:26am
10-12B/A
EX-99.1
71awvyxlwj lfsxk
24 Aug 22
Registration of securities (amended)
5:03pm